The global women health therapeutics market is anticipated to grow at a considerable CAGR of 5.3% during the forecast period. One of the core factors supporting the growth of the market includes the rising adoption of several strategic initiatives such as partnerships, product launches, and others by market players globally. For instance, in August 2021, Agile Therapeutcs, Inc. partnered with Pandia Health to establish a telehealth relationship for Agile. Telehealth provides a point of access to Twirla (levonorgestrel and Ethinyl estradiol) transdermal system) for women. In April 2021, Carestream Health entered a partnership with Ziehm Imaging to provide Ziehm Vision RFD C-arm, a surgical imaging system included in the company’s mobile and fluoroscopic product offerings for ensuring exceptional image quality and reducing exposure significantly. Further, in January 2021, Reckitt Benckiser Group completed the acquisition of a female sexual wellness brand in the US named Queen V that focuses on the vaginal health of women.
Browse the full report description “Global Women Health Therapeutics Market Size, Share & Trends Analysis Report by Type (Infection, Pregnancy, and Oncology), and by End-User (Hospitals and Clinics and Ambulatory Centers) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/women-health-therapeutics-market-size
Additionally, in June 2021, OWN Your Health entered an exclusive agreement with Hologic's Project Health Equality public health program. The collaboration aims to raise awareness about disparities in healthcare quality received by Black women in the US for breast, cervical, and uterine fibroids. Similarly, in November 2020, Hologic Inc. and RadNet announced a collaboration to advance the development of artificial intelligence tools for breast health. The collaboration will include data sharing, R&D, and an upgrade of RadNet’s fleet of Hologic mammography systems to state-of-the-art imaging technology.
Another factor bolstering the market growth is the introduction of new drug therapies by different market players is expected to boost the market in the coming years. For instance, in May 2020, the Food and Drug Administration (FDA) expanded the approval of olaparib (Lynparza) for the initial treatment of women with advanced ovarian cancer. The decision was made based on the outcomes of the PAOLA-1 trial, which are detailed in this Cancer Currents story. The use of a PARP inhibitor as first-line therapy, maintenance therapy, or both in all three studies significantly reduced the time it took for participants' malignancies to return or worsen. The results of all three trials were recently presented in Barcelona, Spain at the European Society for Medical Oncology (ESMO) Congress 2019.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape- including Abbott Laboratpries Inc., f. Hoffmann-la Roche LTD., Novartis AG, Bayer AG, Eli Lilly and Co., and others.
Key questions addressed by the report
oDeviation from the pre-COVID-19 forecast
oMost affected region and segment
Global Women Health Therapeutics Market Report Segment
By Type
oCervical Cancer
oUterine Cancer
oOvarian Cancer
oVaginal & Vular
By End-User
Global Women Health Therapeutics Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/women-health-therapeutics-market-size